Are Prior Authorizations giving you a

headache and costing you time and money?

We can reduce your prior authorizations from hours to only 1 minute and saving you $80.00 per PA, on average!  AMA

Health plans, employers and government-sponsored health care programs are focusing their attention on optimizing patient outcomes with medications that have established evidence of efficacy and safety, while providing the highest value. Implementation of a well-designed, evidence-based prior authorization program optimizes patient outcomes by ensuring that patients receive the most appropriate medications while reducing waste, error and unnecessary prescription drug use and cost. PRIOR AUTHORIZATION SOFTWARE (PA) is an essential tool that QCP uses to ensure that drug benefits are administered as designed and that plan members receive the medication therapy that is safe, effective for their condition, and provides the greatest value.


 

 Quality.
QCP has had ZERO infractions from FDA inspections in the last decade.

 Experience.
QCP has 40+ years of experience in pharmaceutical wholesale.

 Certified.
QCP is state-licensed and sell in 45 States and the District of Columbia.


“QCP’s Point-of-Care Dispensing model contributed greatly to our MSO’s ability to increase patient prescription compliance to more than 96%, and generic utlization to more than 90%, keeping our patients well, and lowering our price points. As a result of this, our ACO allowed us to manage twice as many patients for them in 2016 than we had in 2015. As a result; I implemented QCP’s in my new house Vida Medical Centers.”

– Jesus Lorites, MD

Calculate Your Potential Savings

Would you like to reduce your time for Prior Authorizations for Specialty Drugs from many hours to only 1 minute?  Calculate savings:

  • Please enter a number greater than or equal to 0.
  • Please enter a number greater than or equal to 0.
  • Please enter answer to security question:

QCP Response From CEO Mike Holmes To COVID-19

March 17, 2020

Greetings,

We have a unique responsibility to support our customers and their patients during this public healthcare crisis.

With a critical role supplying the pharmaceuticals urgently needed to respond to coronavirus, as well as to our pharmacies and clinics who dispense acute and chronic medications that their patients also need, QCP has held multiple meetings over the last few weeks to ensure that our customers needs are met in a safe and timely manner, and that our Employees stay safe and healthy.

No slowdown in service has occurred, and none is expected.

QCP’s office workers began working remotely from home last week and will continue to do so until the threat subsides. Workers at our healthcare repackaging, distribution and CSR center continue to report to work.

Thankfully, no employees have been diagnosed with COVID-19, the respiratory disease caused by the novel strain of the virus, and in fact only 1person has been diagnosed in all of Lucas County, at the time of this writing.

QCP has enacted a pre-established plan for responding to a pandemic based on guidelines passed down to us through our lobbying group, Healthcare Distributors Association, from the Centers for Disease Control and Prevention, and the U.S. Department of Health and Human Services, who view the role of QCP and other pharmaceutical Wholesalers as critical to the health and well-being of all Americans.

QCP’s goal has always been to maintain a 3-month supply of over 90% of its’ fast-moving pre-packaged medications. Still, in light of the pandemic, we have increased our supplies of multiple medications and, while we’ve experienced a slight increase in orders as some customers expect that supply chains could be interrupted, we’ve been able to maintain our inventory levels. To date, QCP has experienced zero issues, and the FDA said only 1 medication is in short-supply due to COVID 19. While the possibility of supply disruptions in the future exists, we are communicating with suppliers and customers, and will exhaust all efforts to mitigate any issues that may occur.